Y0000366
Isradipine
European Pharmacopoeia (EP) Reference Standard
别名:
4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C19H21N3O5
CAS Number:
分子量:
371.39
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
isradipine
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C
InChI
1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
InChI key
HMJIYCCIJYRONP-UHFFFAOYSA-N
基因信息
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Isradipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
L-type calcium channel blocker; antihypertensive.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
H Sinzinger et al.
Journal of cardiovascular pharmacology, 19 Suppl 3, S29-S31 (1992-01-01)
Isradipine, a calcium antagonist of the dihydropyridine type, shows antiatherosclerotic actions that interfere with all three main mechanisms of atherosclerosis. These actions are mediated by the release of prostaglandin I2 and endothelium-derived relaxing factor, and the subsequent elevation of intracellular
L Hansson
Acta anaesthesiologica Scandinavica. Supplementum, 99, 26-28 (1993-01-01)
Isradipine is a new dihydropyridine-derived calcium antagonist. It possesses marked vascular selectivity, resulting in a powerful vasodilating action, whereas, in practical terms, it is devoid of cardiac effects. The usefulness of isradipine in the treatment of arterial hypertension is well
Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.
Thimmappa S Anekonda et al.
Biochimica et biophysica acta, 1812(12), 1584-1590 (2011-09-20)
Alzheimer's disease is the most devastating neurodegenerative disorder in the elderly, yet treatment options are severely limited. The drug development effort to modify Alzheimer's disease pathology by intervention at beta amyloid production sites has been largely ineffective or inconclusive. The
R Hirschberger
Fortschritte der Medizin, 111(30), 481-484 (1993-10-30)
The newly developed sustained-release form of isradipine (Vascal uno/Lomir SRO) releases the active substance continuously from a gel matrix over a period of 24 hours. In comparison with the standard formulation, the absolute bioavailability of the sustained-release preparation is somewhat
P Lund-Johansen
American journal of hypertension, 6(7 Pt 2), 294S-299S (1993-07-01)
Isradipine is a dihydropyridine calcium antagonist used for the treatment of hypertension. It is highly selective for vascular smooth muscle, more than cardiac muscle, and thus, lowers systemic blood pressure by reducing peripheral vascular resistance. Isradipine has less negative exotropic
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持